Aptevo Therapeutics (United states)

Recent papers from Aptevo Therapeutics (United states)

1. Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular OutcomesJournal of the American College of Cardiology · 2013
2. A phase I/IIa, image-guided, alpha-particle therapy study of [ ²⁰³ Pb]Pb-PSV359 and [ ²¹² Pb]Pb-PSV359 in patients with solid tumors that are known to be fibroblast activation protein (FAP)–positive.Journal of Clinical Oncology · 2026
3. A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [ ²¹² Pb]VMT01 melanocortin-1-receptor–targeted, image-guided, alpha-particle therapy in subjects with previously treated unresectable or metastatic melanoma.Journal of Clinical Oncology · 2026
4. Cohort-level safety and efficacy results for [ ²¹² Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)–expressing neuroendocrine tumors (NETs): Cohorts 1–3.Journal of Clinical Oncology · 2026
5. Abstract 405: (Z)-endoxifen modulates estrogen receptor and cell-cycle signaling to induce synergistic antiproliferative effects with CDK4/6 inhibition in endometrial cancer models.Cancer Research · 2026
6. Safety and preliminary efficacy results of [ ²¹² Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs).Journal of Clinical Oncology · 2026
7. Constructing the cure: engineering the next wave of antibody and cellular immune therapiesJournal for ImmunoTherapy of Cancer · 2025
8. Advancing Newborn Screening in Washington State: A Novel Multiplexed LC-MS/MS Proteomic Assay for Wilson Disease and Inborn Errors of ImmunityInternational Journal of Neonatal Screening · 2025
9. Abstract CT205: Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trialCancer Research · 2024
10. Appeal of Tobacco Quitline Services Among Low-Income SmokersPreventing Chronic Disease · 2023
11. Novel immunodeficiency caused by homozygous mutation in SLC19A1 encoding the reduced folate carrierBlood · 2023
12. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 TrialThe Journal of Clinical Endocrinology & Metabolism · 2023
13. The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical StudiesMolecular Cancer Therapeutics · 2022
14. Circuit analysis reveals a neural pathway for light avoidance in Drosophila larvaeNature Communications · 2022
15. Pharmacokinetics and Macrophage Inhibitory Cytokine‐1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT‐232) in Fed and Fasted Healthy SubjectsClinical Pharmacology in Drug Development · 2022
16. Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMAFrontiers in Oncology · 2022
17. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulationNature Communications · 2021
18. Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple MyelomaFrontiers in Oncology · 2021
19. Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registryArthritis Research & Therapy · 2021
20. A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCancers · 2021